首页> 外国专利> DERIVATIVES OF N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO1,2-APYRIDINE-2-CARBOXAMIDES,PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF

DERIVATIVES OF N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO1,2-APYRIDINE-2-CARBOXAMIDES,PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF

机译:N-杂环-6-杂环-咪唑并[1,2-A]吡啶-2-氨基甲酸酯的衍生物,制备及其治疗性应用

摘要

N-Heterocyclic-imidazo[1,2-a]pyridine-2-carboxamide compounds (I) and their acid or base addition salts are new. N-Heterocyclic-imidazo[1,2-a]pyridine-2-carboxamide compounds of formula (I) and their acid or base addition salts are new. X : heterocyclic group optionally substituted by halo, 1-6C alkoxy, 1-6C alkyl, NR aR b, CN, oxido or COOR 8, where the alkyl or alkoxy is optionally substituted by halo; R 1H, halo, 1-6C alkoxy, 1-6C alkyl, amino or NR aR b, where the alkyl or alkoxy is optionally substituted by halo, OH, amino or 1-6C alkoxy; R 2either a heterocyclic or a heteroaromatic group (both optionally substituted by OH, 1-6C alkyl, 1-6C alkoxy, CN, NR aR b, -CO-R 5, -CO-NR 6R 7, -CO-O-R 8or -NR 9-CO-R 1 0, where the alkyl or alkoxy is optionally substituted by halo, OH, NR aR bor oxido); R 3H, 1-6C alkyl, 1-6C alkoxy or halo; R 4H, 1-4C alkyl, 1-4C alkoxy or F; R 5H, phenyl or 1-6C alkyl; either R 6, R 7H or 1-6C alkyl; or NR 6R 74-7 membered ring comprising optionally other heteroatoms of N, O or S; R 81-6C alkyl; R 9, R 1 0H or 1-6C alkyl; either R aR bH or 1-6C alkyl; or NR aR b4-7 membered ring comprising optionally other heteroatoms of N, O or S. . An independent claim is included for intermediate compounds (A) of 6-(6-{[(1,1-dimethylethoxy)carbonyl]amino}pyridin-2-yl)imidazo[1,2-a]pyridine-2-carboxylic acid, (6-pyridin-2-yl)imidazo[1,2-a]pyridine-2-carboxylic acid, 6-(1-triphenylmethyl-1H-imidazol-4-yl)imidazo[1,2-a]pyridine-2-carboxylic acid, 6-(2-{[(1,1-dimethylethoxy)carbonyl]amino}-thiazol-4-yl)imidazo[1,2-a]pyridine-2-carboxylic acid, 6-(1H-pyrrol-3-yl)imidazo[1,2-a]pyridine-2-carboxylic acid, 6-(1H-pyrazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylic acid, 6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-2-carboxylic acid, 6-(furan-2-yl)imidazo[1,2-a]pyridine-2-carboxylic acid, 6-(furan-3-yl)imidazo[1,2-a]pyridine-2-carboxylic acid, 6-[5-(hydroxymethyl)furan-2-yl]imidazo[1,2-a]pyridine-2-carboxylic acid, 6-(thiophen-3-yl)imidazo[1,2-a]pyridine-2-carboxylic acid, 6-(oxazol-2-yl)imidazo[1,2-a]pyridine-2-carboxylic acid, 6-(1H-1,2, 4-triazol-3-yl)imidazo[1,2-a]pyridine-2-carboxylic acid, 6-(1H-1,2,3-triazol-4-yl)imidazo[1,2-a]pyridine-2-carboxylic acid, 6-iodo-N-(isoxazol-4-yl)imidazo[1,2-a]pyridine-2-carboxamide, 6-iodo-N-(thiazol-2-yl)imidazo[1,2-a]pyridine-2-carboxamide, 6-iodo-N-(pyridin-2-yl)imidazo[1,2-a]pyridine-2-carboxamide, 6-trimethylstannyl-N-(pyridin-2-yl)imidazo[1,2-a]pyridine-2-carboxamide, hydrobromide of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-imidazo[1,2-a]pyridine-2-ethyl carboxylate and 2-ethoxycarbonyl-imidazo[1,2-a]pyridine-6-boronic acid. [Image] ACTIVITY : Neuroprotective; Cerebroprotective; Anticonvulsant; Neuroleptic; Antiinflammatory; Osteopathic; Cytostatic; Antiparkinsonian; Nootropic; Antidepressant; Antiaddictive; Tranquilizer; CNS-Gen.; Vasotropic; Antiarteriosclerotic; Antiarthritic; Antirheumatic; Gastrointestinal-Gen; Antiulcer; Gastrointestinal-Gen.; Antiallergic; Antiasthmatic; Immunosuppressive; Antidiabetic; Dermatological; Endocrine-Gen; Immunusuppressant; Immunomodulator. MECHANISM OF ACTION : Nuclear receptor related protein 1 (NURR1) modulator; Hippocampus zinc finger protein 3 (HZF-3) modulator; Nuclear receptor of T-cells (NOT) modulator; Regenerating liver nuclear receptor 1 (RNR1) modulator; Transcriptionally inducible nuclear receptor (TINUR) modulator; Nuclear receptor subfamily 4, group A, member 2 (NR4A2) modulator. The ability of (I) to modulate nuclear receptor related protein 1 was tested using N2A cell lines. The results showed that the 7-(1H-imidazol-4-yl)-N-(pyridin-2-yl)imidazo[1,2-a]pyridine-2-carboxamide exhibited an EC 5 0value of 0.8 nM.
机译:N-杂环-咪唑并[1,2-a]吡啶-2-羧酰胺化合物(I)及其酸或碱加成盐是新的。式(I)的N-杂环-咪唑并[1,2-a]吡啶-2-甲酰胺化合物及其酸或碱加成盐是新的。 X:任选地被卤素,1-6C烷氧基,1-6C烷基,NR a R b,CN,氧化或COOR 8取代的杂环基,其中烷基或烷氧基任选地被卤素取代; R 1H,卤素,1-6C烷氧基,1-6C烷基,氨基或NR aR b,其中烷基或烷氧基任选地被卤素,OH,氨基或1-6C烷氧基取代; R 2为杂环或杂芳族基团(均任选被OH,1-6C烷基,1-6C烷氧基,CN,NR aR b,-CO-R 5,-CO-NR 6R 7,-CO-OR 8或-取代) NR 9-CO-R 1 0,其中烷基或烷氧基任选地被卤素,OH,NR aR硼氧化物取代); R 3H,1-6C烷基,1-6C烷氧基或卤素; R 4H,1-4C烷基,1-4C烷氧基或F; R 5H,苯基或1-6C烷基; R 6,R 7H或1-6C烷基;或NR 6R 74-7元环,其任选地包含N,O或S的其他杂原子;或R 81-6C烷基; R 9,R 1 0H或1-6C烷基; R aR bH或1-6C烷基;或NR aR b4-7元环,其任选地包含N,O或S的其他杂原子。包括关于6-(6-{[((1,1-二甲基乙氧基)羰基]氨基}吡啶-2-基)咪唑并[1,2-a]吡啶-2-羧酸的中间体化合物(A)的独立权利要求。 ,(6-吡啶-2-基)咪唑并[1,2-a]吡啶-2-羧酸,6-(1-三苯基甲基-1H-咪唑-4-基)咪唑并[1,2-a]吡啶- 2-羧酸6-(2-{[((1,1-二甲基乙氧基)羰基]氨基}-噻唑-4-基)咪唑并[1,2-a]吡啶-2-羧酸6-(1H-吡咯-3-基)咪唑并[1,2-a]吡啶-2-羧酸6-(1H-吡唑-3-基)咪唑并[1,2-a]吡啶-2-羧酸6-( 1H-吡唑-4-基)咪唑并[1,2-a]吡啶-2-羧酸6-(呋喃-2-基)咪唑并[1,2-a]吡啶-2-羧酸6-(呋喃-3-基)咪唑并[1,2-a]吡啶-2-羧酸,6- [5-(羟甲基)呋喃-2-基]咪唑并[1,2-a]吡啶-2-羧酸, 6-(噻吩-3-基)咪唑并[1,2-a]吡啶-2-羧酸,6-(恶唑-2-基)咪唑并[1,2-a]吡啶-2-羧酸,6- (1H-1,2,4-三唑-3-基)咪唑并[1,2-a]吡啶-2-羧酸,6-(1H-1,2,3-三唑-4-基)咪唑并[1 ,2-a]吡啶-2 -羧酸,6-碘-N-(异恶唑-4-基)咪唑并[1,2-a]吡啶-2-甲酰胺,6-碘-N-(噻唑-2-基)咪唑并[1,2- a]吡啶-2-甲酰胺,6-碘-N-(吡啶-2-基)咪唑[1,2-a]吡啶-2-甲酰胺,6-三甲基锡烷基-N-(吡啶-2-基)咪唑[ 1,2-a]吡啶-2-羧酰胺,6-(4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基)-咪唑并[1,2-a]吡啶-的氢溴酸盐羧酸2-乙基酯和2-乙氧基羰基-咪唑并[1,2-a]吡啶-6-硼酸。活动:神经保护作用;脑保护抗惊厥药;抗精神病药;消炎(药;整骨;细胞抑制反帕金森病;促智;抗抑郁药反吸毒镇静剂; CNS-Gen .;变压性抗动脉硬化;抗关节炎抗风湿;胃肠源;抗溃疡;胃肠源抗过敏;抗哮喘免疫抑制抗糖尿病皮肤;内分泌素免疫抑制剂免疫调节剂。作用机理:核受体相关蛋白1(NURR1)调节剂;海马锌指蛋白3(HZF-3)调节剂; T细胞核受体(NOT)调节剂;再生肝核受体1(RNR1)调节剂;转录诱导核受体(TINUR)调节剂;核受体亚家族4,A组,成员2(NR4A2)调节剂。使用N2A细胞系测试了(I)调节核受体相关蛋白1的能力。结果显示7-(1H-咪唑-4-基)-N-(吡啶-2-基)咪唑并[1,2-a]吡啶-2-甲酰胺的EC 5 0值为0.8 nM。

著录项

  • 公开/公告号ZA201004646B

    专利类型

  • 公开/公告日2011-09-28

    原文格式PDF

  • 申请/专利权人 SANOFI-AVENTIS;

    申请/专利号ZA20100004646

  • 发明设计人 PEYRONEL JEAN-FRANCOIS;

    申请日2010-07-01

  • 分类号C07D;A61K;A61P;C07F;

  • 国家 ZA

  • 入库时间 2022-08-21 18:04:15

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号